Clinical trial · Observational
Folfiri as Third Line of Treatment
FOLFIRI as a Second-line Therapy in Patients With Docetaxel-pretreated Gastric Cancer
NCT03486379CI-TRIAL-00032327completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to investigate the activity of Folfiri as Third line of treatment in mGC progressed after ramuciramb-based second line.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Ramucirumab | — | UNRESOLVED | — |
| Third Line | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- response rate (confirmed complete and partial response).
- timeFrame
- From date of enrollment to best radiological evaluation, up to 12 months
- description
- rate of patients with complete or partial response
Secondary outcomes (3)
- measure
- Progression free survival
- timeFrame
- From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
- description
- Time from start of treatment to Progression or death
- measure
- Overall survival
- timeFrame
- From date of enrollment until the date of death from any cause, whichever came first, assessed up to 12 months
- description
- Time from start of treatment to Death for any cause
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically confirmed, ramucirumab pretreated metastatic gastric cancer who received * Eastern Cooperative Oncology Group performance status ≤2 (ECOG PS) * aged \> 18 years * neutrophil count ≥1500/μl * platelet count ≥100 000/μl), * renal (serum creatinine ≤1.5 mg/dl) * liver (serum bilirubin ≤2 mg/dL) functions * normal cardiac function, * absence of second primary tumor other than non-melanoma skin cancer * no concurrent uncontrolled medical illness. Exclusion Criteria: * Eastern Cooperative Oncology Group performance status \>2 (ECOG PS) * No prior treatment with ramucirumab * operable metastatic disease were excluded from the study * severe cardiac dysfunction, congestive heart failure or a recent myocardial infarction * uncontrolled sites of infection.
References
Publications (0)
Data not yet available
No reference posted for this study.